Refractory Kidney Medullary Carcinoma clinical trials at UCSF

1 research study open to eligible people

Refractory Kidney Medullary Carcinoma is a type of cancer that can be difficult to treat. UCSF is recruiting patients for a clinical trial that studies how well a combination of tiragolumab and atezolizumab works in treating this cancer. The trial is open to children and adults who have relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.

Showing trials for

  • Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

    open to eligible people ages 12 months and up

    This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that that has either come back (relapsed) or does not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

    San Francisco, California and other locations

Our lead scientists for Refractory Kidney Medullary Carcinoma research studies include .

Last updated: